Challenges Facing JAK Inhibitor Therapy for Myeloproliferative Neoplasms

Abstract excerpt

William Vainchenker discovered the gain-of-function mutation in the gene encoding Janus kinase (JAK) 2 (JAK2 V617F) in early 2004 (reported in 2005)1 and subsequently described its association with BCR-ABL1–negative myeloproliferative neoplasms and its ability to induce erythrocytosis in mice. At that time, many researchers hoped that a specific targeted agent would be developed for these neoplasms, similar to...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Chronic Myeloid Leukemia Treatments
• Share to Kruppel-like factors research
• Share to Myeloproliferative Neoplasms: Diagnosis and Treatment